Supercharge Your Innovation With Domain-Expert AI Agents!

Xanthine Oxidase Inhibitor

a technology of xanthine oxidase and xanthine, which is applied in the direction of drug composition, extracellular fluid disorder, metabolic disorder, etc., can solve the problems of increased chance of side effects, lesion, and hepatopathy of allopurinol,

Inactive Publication Date: 2007-11-15
NIPPON CHEMIPHAR CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is well known that allopurinol causes side effects such as lesion, hepatopathy, and myelogenetic troubles.
Therefore, the chance of causing side effects increases.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Xanthine Oxidase Inhibitor
  • Xanthine Oxidase Inhibitor
  • Xanthine Oxidase Inhibitor

Examples

Experimental program
Comparison scheme
Effect test

example 1

8-(4-Isobutoxy-3-nitrophenyl)-6-chloropurine(A) and 6-amino-8-(4-isobutoxy-3-nitrophenyl)15 oxazolo[4,5-d]pyrimidine(B)

(1) Methyl 4-hydroxy-3-nitrobenzoate

[0071] 4-Hydroxy-3-nitrobenzoic acid (10.0 g, 54.6 mmol) was suspended in methanol (60 mL). After addition of conc. sulfuric acid (0.1 mL), the suspension was heated overnight under reflux. The methanol was distilled off under reduced pressure. The residue was dissolved in ethyl acetate (40 mL), washed successively with aqueous sodium hydrogen carbonate (20 mL×2) and saturated aqueous brine (20 mL), and dried over anhydrous sodium sulfate. The solvent was distilled off under reduced pressure, to give 6.27 g (yield 58%) of the desired compound in the form of a pale brown crystalline product.

[0072] M. p. 72-73° C. 1H NMR (CDCl3, 400 MHz) δ: 3.95 (3H, s), 7.22 (1H, d, J=9 Hz), 8.24 (1H, dd, J=2 Hz, 9 Hz), 8.83 (1H, d, J=2 Hz), 10.89 (1H, s).

(2) Methyl 4-isobutyloxy-3-nitrobenzoate

[0073] Isobutyl bromide (10.5 mL, 95.8 mmol) was ...

example 2

8-(4-Isobutoxy-3-nitrophenyl)-6-hydroxypurine

[0085] A suspension of 8-(4-isobutoxy-3-nitrophenyl)-6-chloropurine (30 mg, 0.086 mmol) in aqueous 2M hydrochloric acid (4.5 mL) was heated to 120° C. for 3 hours under stirring. The suspension was then cooled to room temperature. The precipitated solid product was collected by filtration, washed with water, and dried in air. The dried product was heated to 100° C. after addition of aqueous 2M hydrochloric acid (27 mL). The insolubles were removed while the aqueous portion was still hot. The filtrate was stirred overnight. The precipitated solid product was collected by filtration, washed with water, and dried in air, to give 12 mg (yield 43%) of the desired compound in the form of a yellow powdery product.

[0086] hu 1H NMR (DMSO-d6, 400 MHz) δ: 1.00 (6H, d, J=7 Hz), 2.0-2.2 (1H, m), 4.03 (2H, d, J=6 Hz), 7.55 (1H, d, J=9 Hz), 8.02 (1H, s), 8.39 (1H, dd, J=2 Hz, 9 Hz), 8.65 (1H, d, J=2 Hz), 12.28 (1H, s).

[0087] FAB-MS (m / e): 330 (M+1). ...

example 3

8-(4-Isobutoxy-3-nitrophenyl)-1H-benzimidazole

[0088] 1,2-Phenylenediamine (1.09 g, 10.1 mmol) was dissolved in THF (20 mL). The solution was cooled with ice water, and to the cooled solution was dropwise added to a solution of 4-isobutoxy-3-nitrobenzoyl chloride (1.00 mmol) in THF (3 mL) for more than 30 min. The mixture was then stirred for 3 hours under cooling with ice-water. The solvent was distilled off under reduced pressure. The residue was suspended in water (20 mL) and stirred for 30 min., at room temperature. The obtained crystalline product was collected by filtration, washed with water (5 mL×3), and dried at room temperature under reduced pressure, to give 291 mg (yield 88%) of the desired amide product in the form of a pale yellow crystalline product.

[0089] The amide product (165 mg, 0.50 mmol) and phosphoryl chloride (3.0 mL) were together heated under reflux for 3 hours, and then allowed to stand and cooled to room temperature. The reaction mixture was poured into i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to compounds of the following formula (I) or their salts: in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which may have a substituent or the like; R2 is halogen, nitro, cyano, carboxyl, or the like; R3 is hydrogen, halogen, hydroxyl, amino, carboxyl, or the like; X is NR11, oxygen, or sulfur, in which R11 is hydrogen, or an alkyl group having 1-8 carbon atom which may have a substituent; and each of Y and Z is CR12 or nitrogen, in which R12 has the same meaning as R3 above, and a xanthine oxidase inhibitor containing the compound as an active ingredient.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a xanthine oxidase inhibitor. BACKGROUND OF THE INVENTION [0002] The hyperuricemia causes gout and renal insufficiency and is also considered to be a factor causing coronary disease. Furthermore, the hyperuricemia is suggested to closely relate to the development of diseases of adults such as hypertension. Therefore, treatment of the hyperuricemia can be effective not only for treating gout but also for preventing various diseases relating to daily nutrition and the advancement of age. [0003] Presently, the hyperuricemia is treated using an inhibitor for inhibiting production of uremic acid such as allopurinol and an accelerator for uricotelism such as benzbromalone. However, it is well known that allopurinol causes side effects such as lesion, hepatopathy, and myelogenetic troubles. The allopurinol and its metabolic product (oxypurinol) are excreted from the kidneys. However, if the excretion of uric acid decreases, the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/416A61K31/421A61K31/426A61K31/437A61K31/52A61P7/00C07D221/02C07D235/00C07D263/54C07D277/62C07D473/00A61P3/00A61P13/12A61P19/06A61P43/00C07D235/18C07D263/56C07D263/57C07D277/66C07D401/14C07D471/04C07D473/30C07D473/34C07D473/40C07D487/04C07D498/04C07D513/04
CPCC07D235/18C07D263/57C07D277/66C07D401/14C07D471/04C07D513/04C07D473/30C07D473/34C07D473/40C07D487/04C07D473/00A61P13/12A61P19/06A61P3/00A61P43/00A61P7/00A61P9/00C07D498/04C07D263/56
Inventor YOSHIDA, SHINICHITENDO, ATSUSHIKOBAYASHI, KUNIOMOCHIDUKI, NOBUTAKAYAMAKAWA, TOMIOSHINOHARA, YORIKO
Owner NIPPON CHEMIPHAR CO LTD
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More